Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 74

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Hodgkin's disease

Not recruiting

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Fungal infection

Not recruiting

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Hodgkin's disease+1

Not recruiting

Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Genmab A/S

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.